<p>Agios Pharmaceuticals, Inc.（纳斯达克代码：AGIO - 获取免费报告）在周三市场开盘前股价跳涨，此前公司发布了超出预期的财报。该股票此前收于 24.80 美元，但开盘时为 26.50 美元。Agios Pharmaceuticals 的股票最后交易价格为 27.3740 美元，成交量为 437,023 股。</p>
<p>获取 <strong>Agios Pharmaceuticals</strong> 的提醒：</p>
<p>这家生物制药公司报告本季度每股收益为（$1.69），超出分析师一致预期的（$1.82）0.13 美元。该公司本季度的收入为 2075 万美元，而分析师预期为 1391 万美元。Agios Pharmaceuticals 的净利润率为负 764.01%，股本回报率为负 31.07%。与去年同期相比，该公司的季度收入增长了 137.7%。</p>
<h2>分析师设定新目标价</h2>
<p>多家股票研究分析师最近对 AGIO 股票发表了看法。华尔街 Zen 在 3 月 22 日的报告中将 Agios Pharmaceuticals 的股票评级从 “卖出” 上调至 “持有”。花旗集团在 3 月 5 日的报告中将 Agios Pharmaceuticals 的目标价从 38.00 美元上调至 46.00 美元，并给予该公司 “买入” 评级。摩根大通在 4 月 6 日的报告中将 Agios Pharmaceuticals 的目标价从 31.00 美元上调至 36.00 美元，并给予该公司 “中性” 评级。Weiss Ratings 在 3 月 27 日的报告中重新发布了对 Agios Pharmaceuticals 的 “卖出（d）” 评级。最后，HC Wainwright 在 4 月 20 日的报告中将 Agios Pharmaceuticals 的目标价从 65.00 美元下调至 50.00 美元，并对该股票设定了 “买入” 评级。六位投资分析师对该股票给予了 “买入” 评级，四位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat 的数据，该公司的平均评级为 “持有”，共识目标价为 41.78 美元。</p>
<p><strong>阅读我们对 AGIO 的最新分析</strong></p>
<h2>内部人士下注</h2>
<p>在其他新闻中，内部人士 James William Burns 在 4 月 2 日的交易中出售了 3280 股公司的股票。股票以平均价格 34.71 美元出售，总价值为 113,848.80 美元。出售后，该内部人士直接持有 49,306 股公司股票，价值为 1,711,411.26 美元。这代表其持股减少了 6.24%。该交易已在与证券交易委员会的法律文件中披露，文件可通过 SEC 网站访问。该交易是在预先安排的 10b5-1 交易计划下执行的。出售是为了覆盖与股权奖励归属相关的税收扣缴义务。此外，内部人士 Sarah Gheuens 在 4 月 2 日的交易中出售了 2940 股公司的股票。该股票以平均价格 34.71 美元出售，总价值为 102,047.40 美元。出售完成后，该内部人士在公司中持有 80,277 股，价值约为 2,786,414.67 美元。这代表其持股减少了 3.53%。该交易的披露信息可在 SEC 文件中找到。该交易是在预先安排的 10b5-1 交易计划下执行的。出售是为了覆盖与股权奖励归属相关的税收扣缴义务。在过去三个月中，内部人士出售了价值 520,405 美元的 15,582 股公司股票。公司内部人士持有公司股票的 4.93%。</p>
<h2>机构投资者对 Agios Pharmaceuticals 的看法</h2>
<p>几家对冲基金最近买入和卖出了 AGIO 的股票。AQR Capital Management LLC 在第一季度将其在 Agios Pharmaceuticals 的持仓增加了 66.8%。AQR Capital Management LLC 现在持有 51,489 股该生物制药公司的股票，价值为 1,498,000 美元，此前在上一季度购买了额外的 20,625 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度将其在 Agios Pharmaceuticals 的持仓增加了 7.2%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.现在持有 43,327 股该生物制药公司的股票，价值为 1,274,000 美元，此前在上一季度购买了额外的 2,920 股。NewEdge Advisors LLC 在第一季度购买了 Agios Pharmaceuticals 的新股份，价值约为 40,000 美元。高盛集团在第一季度将其在 Agios Pharmaceuticals 的持仓增加了 16.1%。高盛集团现在持有 658,652 股该生物制药公司的股票，价值为 19,299,000 美元，此前在上一季度购买了额外的 91,482 股。最后，Woodline Partners LP 在第一季度购买了 Agios Pharmaceuticals 的新股份，价值约为 597,000 美元。</p>
<h2>Agios Pharmaceuticals 股价上涨 11.0%</h2>
<p>该公司 50 日简单移动平均线为 29.87 美元，200 日简单移动平均线为 31.07 美元。该公司的市值为 16.4 亿美元，市盈率为-3.86，贝塔值为 0.79。</p>
<h2>Agios Pharmaceuticals 公司简介</h2>
<p>（获取免费报告）</p>
<p>Agios Pharmaceuticals, Inc 是一家生物制药公司，成立于 2008 年，源于 Dana-Farber 癌症研究所和 Broad Institute 的研究。公司总部位于马萨诸塞州剑桥，Agios 专注于理解和针对细胞代谢，以开发针对癌症和罕见遗传疾病的新疗法。该公司的科学平台整合了基因组发现、代谢分析和精准医学方法，以识别和推进能够纠正或利用代谢功能障碍的小分子候选药物。</p>
<p>Agios 的主要产品是针对特定癌症突变的 IDH（异柠檬酸脱氢酶）抑制剂。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票比 Agios Pharmaceuticals 更好</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Agios Pharmaceuticals 吗？</h2>
<p>在考虑 Agios Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Agios Pharmaceuticals 并不在名单上。</p>
<p>虽然 Agios Pharmaceuticals 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Agios制药

<p>Agios 制药（NASDAQ:AGIO）股价飙升至 26.50 美元，此前报告的每股收益为（1.69 美元），超出预期的（1.82 美元）。收入达到 2075 万美元，超过了 1391 万美元的预测。分析师的评级不一，六位分析师推荐买入，四位分析师建议持有。内部交易中出现了大量销售以覆盖税务义务。机构投资者增加了持股比例，AQR 资本管理公司将其持仓提高了 66.8%。该股票的市值为 16.4 亿美元，交易上涨 11.0%</p>

<p>Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) shares gapped up before the market opened on Wednesday following a better than expected earnings announcement. The stock had previously closed at $24.80, but opened at $26.50. Agios Pharmaceuticals shares last traded at $27.3740, with a volume of 437,023 shares traded.</p>
<div class="lb-trans"><p>Agios Pharmaceuticals, Inc.（纳斯达克代码：AGIO - 获取免费报告）在周三市场开盘前股价跳涨，此前公司发布了超出预期的财报。该股票此前收于 24.80 美元，但开盘时为 26.50 美元。Agios Pharmaceuticals 的股票最后交易价格为 27.3740 美元，成交量为 437,023 股。</p>
</div><p>Get <strong>Agios Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Agios Pharmaceuticals</strong> 的提醒：</p>
</div><p>The biopharmaceutical company reported ($1.69) earnings per share for the quarter, beating analysts' consensus estimates of ($1.82) by $0.13. The firm had revenue of $20.75 million for the quarter, compared to analyst estimates of $13.91 million. Agios Pharmaceuticals had a negative net margin of 764.01% and a negative return on equity of 31.07%. The firm's revenue for the quarter was up 137.7% compared to the same quarter last year.</p>
<div class="lb-trans"><p>这家生物制药公司报告本季度每股收益为（$1.69），超出分析师一致预期的（$1.82）0.13 美元。该公司本季度的收入为 2075 万美元，而分析师预期为 1391 万美元。Agios Pharmaceuticals 的净利润率为负 764.01%，股本回报率为负 31.07%。与去年同期相比，该公司的季度收入增长了 137.7%。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>A number of equities research analysts have recently weighed in on AGIO shares. Wall Street Zen raised shares of Agios Pharmaceuticals from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Sunday, March 22nd. Citigroup boosted their price objective on shares of Agios Pharmaceuticals from $38.00 to $46.00 and gave the company a &#34;buy&#34; rating in a report on Thursday, March 5th. JPMorgan Chase &amp; Co. boosted their price objective on shares of Agios Pharmaceuticals from $31.00 to $36.00 and gave the company a &#34;neutral&#34; rating in a report on Monday, April 6th. Weiss Ratings reissued a &#34;sell (d)&#34; rating on shares of Agios Pharmaceuticals in a report on Friday, March 27th. Finally, HC Wainwright dropped their price objective on shares of Agios Pharmaceuticals from $65.00 to $50.00 and set a &#34;buy&#34; rating on the stock in a report on Monday, April 20th. Six investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of &#34;Hold&#34; and a consensus target price of $41.78.</p>
<div class="lb-trans"><p>多家股票研究分析师最近对 AGIO 股票发表了看法。华尔街 Zen 在 3 月 22 日的报告中将 Agios Pharmaceuticals 的股票评级从 “卖出” 上调至 “持有”。花旗集团在 3 月 5 日的报告中将 Agios Pharmaceuticals 的目标价从 38.00 美元上调至 46.00 美元，并给予该公司 “买入” 评级。摩根大通在 4 月 6 日的报告中将 Agios Pharmaceuticals 的目标价从 31.00 美元上调至 36.00 美元，并给予该公司 “中性” 评级。Weiss Ratings 在 3 月 27 日的报告中重新发布了对 Agios Pharmaceuticals 的 “卖出（d）” 评级。最后，HC Wainwright 在 4 月 20 日的报告中将 Agios Pharmaceuticals 的目标价从 65.00 美元下调至 50.00 美元，并对该股票设定了 “买入” 评级。六位投资分析师对该股票给予了 “买入” 评级，四位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat 的数据，该公司的平均评级为 “持有”，共识目标价为 41.78 美元。</p>
</div><p><strong>Read Our Latest Analysis on AGIO</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 AGIO 的最新分析</strong></p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other news, insider James William Burns sold 3,280 shares of the company's stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $34.71, for a total value of $113,848.80. Following the sale, the insider directly owned 49,306 shares of the company's stock, valued at $1,711,411.26. This represents a 6.24% decrease in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Sarah Gheuens sold 2,940 shares of the company's stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $34.71, for a total value of $102,047.40. Following the completion of the sale, the insider owned 80,277 shares in the company, valued at approximately $2,786,414.67. This represents a 3.53% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 15,582 shares of company stock worth $520,405. Company insiders own 4.93% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，内部人士 James William Burns 在 4 月 2 日的交易中出售了 3280 股公司的股票。股票以平均价格 34.71 美元出售，总价值为 113,848.80 美元。出售后，该内部人士直接持有 49,306 股公司股票，价值为 1,711,411.26 美元。这代表其持股减少了 6.24%。该交易已在与证券交易委员会的法律文件中披露，文件可通过 SEC 网站访问。该交易是在预先安排的 10b5-1 交易计划下执行的。出售是为了覆盖与股权奖励归属相关的税收扣缴义务。此外，内部人士 Sarah Gheuens 在 4 月 2 日的交易中出售了 2940 股公司的股票。该股票以平均价格 34.71 美元出售，总价值为 102,047.40 美元。出售完成后，该内部人士在公司中持有 80,277 股，价值约为 2,786,414.67 美元。这代表其持股减少了 3.53%。该交易的披露信息可在 SEC 文件中找到。该交易是在预先安排的 10b5-1 交易计划下执行的。出售是为了覆盖与股权奖励归属相关的税收扣缴义务。在过去三个月中，内部人士出售了价值 520,405 美元的 15,582 股公司股票。公司内部人士持有公司股票的 4.93%。</p>
</div><h2>Institutional Investors Weigh In On Agios Pharmaceuticals</h2>
<div class="lb-trans"><h2>机构投资者对 Agios Pharmaceuticals 的看法</h2>
</div><p>Several hedge funds have recently bought and sold shares of AGIO. AQR Capital Management LLC boosted its position in Agios Pharmaceuticals by 66.8% in the 1st quarter. AQR Capital Management LLC now owns 51,489 shares of the biopharmaceutical company's stock worth $1,498,000 after purchasing an additional 20,625 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Agios Pharmaceuticals by 7.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,327 shares of the biopharmaceutical company's stock worth $1,274,000 after purchasing an additional 2,920 shares in the last quarter. NewEdge Advisors LLC purchased a new stake in Agios Pharmaceuticals in the 1st quarter worth approximately $40,000. Goldman Sachs Group Inc. boosted its position in Agios Pharmaceuticals by 16.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 658,652 shares of the biopharmaceutical company's stock worth $19,299,000 after purchasing an additional 91,482 shares in the last quarter. Finally, Woodline Partners LP purchased a new stake in Agios Pharmaceuticals in the 1st quarter worth approximately $597,000.</p>
<div class="lb-trans"><p>几家对冲基金最近买入和卖出了 AGIO 的股票。AQR Capital Management LLC 在第一季度将其在 Agios Pharmaceuticals 的持仓增加了 66.8%。AQR Capital Management LLC 现在持有 51,489 股该生物制药公司的股票，价值为 1,498,000 美元，此前在上一季度购买了额外的 20,625 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度将其在 Agios Pharmaceuticals 的持仓增加了 7.2%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.现在持有 43,327 股该生物制药公司的股票，价值为 1,274,000 美元，此前在上一季度购买了额外的 2,920 股。NewEdge Advisors LLC 在第一季度购买了 Agios Pharmaceuticals 的新股份，价值约为 40,000 美元。高盛集团在第一季度将其在 Agios Pharmaceuticals 的持仓增加了 16.1%。高盛集团现在持有 658,652 股该生物制药公司的股票，价值为 19,299,000 美元，此前在上一季度购买了额外的 91,482 股。最后，Woodline Partners LP 在第一季度购买了 Agios Pharmaceuticals 的新股份，价值约为 597,000 美元。</p>
</div><h2>Agios Pharmaceuticals Trading Up 11.0%</h2>
<div class="lb-trans"><h2>Agios Pharmaceuticals 股价上涨 11.0%</h2>
</div><p>The company has a 50-day simple moving average of $29.87 and a 200 day simple moving average of $31.07. The firm has a market cap of $1.64 billion, a PE ratio of -3.86 and a beta of 0.79.</p>
<div class="lb-trans"><p>该公司 50 日简单移动平均线为 29.87 美元，200 日简单移动平均线为 31.07 美元。该公司的市值为 16.4 亿美元，市盈率为-3.86，贝塔值为 0.79。</p>
</div><h2>Agios Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Agios Pharmaceuticals 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company's scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.</p>
<div class="lb-trans"><p>Agios Pharmaceuticals, Inc 是一家生物制药公司，成立于 2008 年，源于 Dana-Farber 癌症研究所和 Broad Institute 的研究。公司总部位于马萨诸塞州剑桥，Agios 专注于理解和针对细胞代谢，以开发针对癌症和罕见遗传疾病的新疗法。该公司的科学平台整合了基因组发现、代谢分析和精准医学方法，以识别和推进能够纠正或利用代谢功能障碍的小分子候选药物。</p>
</div><p>Agios's lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.</p>
<div class="lb-trans"><p>Agios 的主要产品是针对特定癌症突变的 IDH（异柠檬酸脱氢酶）抑制剂。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Agios Pharmaceuticals</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Agios Pharmaceuticals 更好</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Agios Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Agios Pharmaceuticals 吗？</h2>
</div><p>Before you consider Agios Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Agios Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agios Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Agios Pharmaceuticals 并不在名单上。</p>
</div><p>While Agios Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Agios Pharmaceuticals 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Agios 制药（NASDAQ:AGIO）股价因盈利超预期而跳空高开